Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Rheumatology Precision Panel > Juvenile Idiopathic Arthritis Precision Panel

Juvenile Idiopathic Arthritis Precision Panel

Juvenile arthritis is a heterogenous group of inflammatory arthritis of unknown etiology, all defined by the presence of at least one inflamed joint persisting more than six weeks.
Rheumatology
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Juvenile arthritis is a heterogenous group of inflammatory arthritis of unknown etiology, all defined by the presence of at least one inflamed joint persisting more than six weeks. Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease in children, with an unpredictable clinical course and the impending risk of impaired joint function. It begins before 16 years of age, and the triggering factor can be a trauma or infection. JIA can be classified in six categories:  

    Systemic arthritis 
    Polyarthritis (rheumatoid factor positive or negative) 
    Oligoarthritis 
    Enthesitis-related arthritis 
    Psoriatic arthritis 
    Undifferentiated arthritis 

  • The prognosis varies depending on the case, but systemic arthritis and rheumatoid factor positive polyarthritis generally show a worse prognosis. The most common mode of inheritance is autosomal recessive.  

  • The Igenomix Juvenile Idiopathic Arthritis Precision Panel can be used to make an accurate and directed diagnosis as well as a differential diagnosis of arthritis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

Indication

  • The Igenomix Juvenile Idiopathic Arthritis Precision Panel is indicated for those patients with a clinical diagnosis or suspicion presenting with or without the following manifestations: 
    • Arthralgias 
    • Rash 
    • Fever 
    • Lymphadenopathy 
    • Arthritis 
    • Pericarditis 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.    
  • Early initiation of multidisciplinary treatment including occupational and physical therapist, pharmacologic treatment with anti-inflammatory drugs to reduce pain and swelling, or even disease-modifying antirheumatic drugs (DMARDs) if there is a high risk of damage in the future. 
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Improvement of delineation of genotype-phenotype correlation. 

Genes & Diseases

Methodology

References

See scientific referrals

Prakken, B., Albani, S., & Martini, A. (2011). Juvenile idiopathic arthritis. Lancet (London, England), 377(9783), 2138–2149. 

Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., Aletaha, D., Aringer, M., Askling, J., Balsa, A., Boers, M., den Broeder, A. A., Buch, M. H., Buttgereit, F., Caporali, R., Cardiel, M. H., … van der Heijde, D. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the rheumatic diseases, 79(6), 685–699. 

Siegel, P., Tencza, M., Apodaca, B., & Poole, J. L. (2017). Effectiveness of Occupational Therapy Interventions for Adults With Rheumatoid Arthritis: A Systematic Review. The American journal of occupational therapy: official publication of the American Occupational Therapy Association, 71(1), 7101180050p1–7101180050p11. 

Thatayatikom, A., & De Leucio, A. (2020). Juvenile Idiopathic Arthritis. In StatPearls. StatPearls Publishing. 

Eng, S. W., Duong, T. T., Rosenberg, A. M., Morris, Q., Yeung, R. S., & REACCH OUT and BBOP Research Consortia (2014). The biologic basis of clinical heterogeneity in juvenile idiopathic arthritis. Arthritis & rheumatology (Hoboken, N.J.), 66(12), 3463–3475. 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information